In HER2+ breast carcinoma, it has been demonstrated that HER2 (unlike EGFR) suppresses cGAS-STING signaling, hindering the cancer cells from producing cytokines, entering senescence, and undergoing apoptosis. This evidence concerns the gene EGFR and breast carcinoma.